- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Vanguard Pharmaceutical Corp.
In an era of aging populations, rising health care costs, and increasing cancer cases Vanguard's mission is to decrease health care expenditures by selling affordable oncology and generic drugs and by investing in research to find a noninvasive cure for cancer.
Generic medicines allow patients to access safe, effective, high-quality medicines at 10%-80% of the price of branded originator medicines. In this way, generic medicines support the sustainability of health care provision and contribute to controlling pharmaceutical expenditure. Vanguard is currently targeting Latin America for its oncology and generic pharmaceutical sales as it is believed to have a substantially unmet demand for advanced generics and entry into the market can be done with relative ease. Latin America is set to emerge as a globally significant market and its generics market is conservatively expected to reach US$6.4 billion by the year-end of 2009.
A noninvasive cure for cancer will revolutionize our health care system by highly reducing hospital stays as patients will not have to go through life threatening chemotherapy and radiation which could save health care systems billions of dollars. Vanguard's team is researching several new technologies such as telomerase inhibitor therapy, nanoparticle therapies, and low power radio frequency radiation. Vanguard plans to partner with established clinical centers and universities to further develop these technologies then license them out. It has also discussed performing trials in Latin American oncology centers.
17503 La Cantera, Parkway Ste. 104 #253
San Antonio, TX 78257 USA